Ameliorative effect of nicergoline on cognitive function through the PI3K/AKT signaling pathway in mouse models of Alzheimer's disease

Zang,Guoyao; Fang,Lizheng; Chen,Liying; Wang,Chenyao

doi:10.3892/mmr.2018.8786

Ameliorative effect of nicergoline on cognitive function through the PI3K/AKT signaling pathway in mouse models of Alzheimer's disease

Authors:
- Guoyao Zang
- Lizheng Fang
- Liying Chen
- Chenyao Wang
View Affiliations

Affiliations: Department of General Practice, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310016, P.R. China, Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310005, P.R. China
Published online on: March 20, 2018 https://doi.org/10.3892/mmr.2018.8786
Pages: 7293-7300

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Alzheimer's disease is one of the most common age‑associated diseases that frequently leads to memory disorders, cognitive decline and dementia. Evidence suggests that nicergoline serves an important role in the apoptosis of hippocampal cells, memory recovery, cognitive function and neuronal survival. However, the signaling pathway affected by nicergoline treatment remains to be elucidated. The purpose of the present study was to investigate the role of nicergoline in the cognitive competence of a mouse model of Alzheimer's disease. The apoptosis rates of hippocampal cells were studied in mice with Alzheimer's disease treated with nicergoline compared with the negative control. Apoptosis‑associated gene expression levels in hippocampal cells, and hippocampus area, were analyzed in the experimental mice. Visual attention and inhibitory control were assessed and neural counting was performed in brain regions of interest. The phosphatidylinositol 3‑kinase (PI3K)/RAC‑α serine/threonine‑protein kinase (AKT) signaling pathway was additionally analyzed in hippocampal cells following treatment with nicergoline. The results of the present study demonstrated that nicergoline ameliorated apoptosis in hippocampal cells and hippocampus tissue in 3xTg‑AD mice with Alzheimer's disease. The data indicated that apoptosis‑associated genes, including caspase‑3, BCL2 associated X, BH3 interacting domain death agonist and caspase‑9, were downregulated in hippocampal cells isolated from nicergoline-treated experimental mice. In addition, the expression levels of inflammatory factors, in addition to oxidative stress, were decreased in hippocampal cells treated with nicergoline. Additionally, amyloid precursor protein accumulation was cleared in the hippocampal area in nicergoline‑treated mice. Nicergoline inhibited neuronal loss and prevented cognitive impairment through the restoration of learning/memory ability. It was additionally demonstrated in the present study that nicergoline improved motor attention impairment and cognitive competence in hippocampal cells by acting on the PI3K/AKT signaling pathway. Therefore, memory recovery, cognitive function and neuronal survival were repaired by nicergoline via inhibition of the PI3K/AKT signaling pathway, suggesting that nicergoline may be an efficient drug for the clinical treatment of patients with Alzheimer's disease.

View Figures

View References

1	Armstrong RA: Survival in the pre-senile dementia frontotemporal lobar degeneration with TDP-43 proteinopathy: Effects of genetic, demographic and neuropathological variables. Folia Neuropathol. 54:137–148. 2016. View Article : Google Scholar : PubMed/NCBI
2	Bando N and Nakamura Y: Preliminary evidence that rivastigmine-induced inhibition of serum butyrylcholinesterase activity improves behavioral symptoms in Japanese patients with Alzheimer's disease. Geriatr Gerontol Int. 17:1306–1312. 2017. View Article : Google Scholar : PubMed/NCBI
3	Verkhratsky A, Rodriguez-Arellano JJ, Parpura V and Zorec R: Astroglial calcium signalling in Alzheimer's disease. Biochem Biophys Res Commun. 483:1005–1012. 2017. View Article : Google Scholar : PubMed/NCBI
4	Cortese GP and Burger C: Neuroinflammatory challenges compromise neuronal function in the aging brain: Postoperative cognitive delirium and Alzheimer's disease. Behav Brain Res. 322:269–279. 2017. View Article : Google Scholar : PubMed/NCBI
5	Pettigrew C, Soldan A, Zhu Y, Wang MC, Brown T, Miller M and Albert M: BIOCARD Research Team: Cognitive reserve and cortical thickness in preclinical Alzheimer's disease. Brain Imaging Behav. 11:357–367. 2017. View Article : Google Scholar : PubMed/NCBI
6	Fritz NE, Kegelmeyer DA, Kloos AD, Linder S, Park A, Kataki M, Adeli A, Agrawal P, Scharre DW and Kostyk SK: Motor performance differentiates individuals with Lewy body dementia, Parkinson's and Alzheimer's disease. Gait Posture. 50:1–7. 2016. View Article : Google Scholar : PubMed/NCBI
7	Stella F, Laks J, Govone JS, de Medeiros K and Forlenza OV: Association of neuropsychiatric syndromes with global clinical deterioration in Alzheimer's disease patients. Int Psychogeriatr. 28:779–786. 2016. View Article : Google Scholar : PubMed/NCBI
8	Garcia KO, Ornellas FL, Martin PK, Patti CL, Mello LE, Frussa-Filho R, Han SW and Longo BM: Therapeutic effects of the transplantation of VEGF overexpressing bone marrow mesenchymal stem cells in the hippocampus of murine model of Alzheimer's disease. Front Aging Neurosci. 6:302014. View Article : Google Scholar : PubMed/NCBI
9	Ramos B, Baglietto-Vargas D, del Rio JC, Moreno-Gonzalez I, Santa-Maria C, Jimenez S, Caballero C, Lopez-Tellez JF, Khan ZU, Ruano D, et al: Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1×APP transgenic model of Alzheimer's disease. Neurobiol Aging. 27:1658–1672. 2006. View Article : Google Scholar : PubMed/NCBI
10	Youn H, Ji I, Ji HP, Markesbery WR and Ji TH: Under-expression of Kalirin-7 Increases iNOS activity in cultured cells and correlates to elevated iNOS activity in Alzheimer's disease hippocampus. J Alzheimers Dis. 12:271–281. 2007. View Article : Google Scholar : PubMed/NCBI
11	Namba T, Maekawa M, Yuasa S, Kohsaka S and Uchino S: The Alzheimer's disease drug memantine increases the number of radial glia-like progenitor cells in adult hippocampus. Glia. 57:1082–1090. 2009. View Article : Google Scholar : PubMed/NCBI
12	Chen J, Shu H, Wang Z, Liu D, Shi Y, Xu L and Zhang Z: Protective effect of APOE epsilon 2 on intrinsic functional connectivity of the entorhinal cortex is associated with better episodic memory in elderly individuals with risk factors for Alzheimer's disease. Oncotarget. 7:58789–58801. 2016.PubMed/NCBI
13	Ando K, Oka M, Ohtake Y, Hayashishita M, Shimizu S, Hisanaga S and Iijima KM: Tau phosphorylation at Alzheimer's disease-related Ser356 contributes to tau stabilization when PAR-1/MARK activity is elevated. Biochem Biophys Res Commun. 478:929–934. 2016. View Article : Google Scholar : PubMed/NCBI
14	Liu W, Zhao J and Lu G: miR-106b inhibits tau phosphorylation at Tyr18 by targeting Fyn in a model of Alzheimer's disease. Biochem Biophys Res Commun. 478:852–857. 2016. View Article : Google Scholar : PubMed/NCBI
15	Absalon S, Kochanek DM, Raghavan V and Krichevsky AM: MiR-26b, upregulated in Alzheimer's disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons. J Neurosci. 33:14645–14659. 2013. View Article : Google Scholar : PubMed/NCBI
16	Jahng GH, Oh J, Lee DW, Kim HG, Rhee HY, Shin W, Paik JW, Lee KM, Park S, Choe BY and Ryu CW: Glutamine and glutamate complex, as measured by functional magnetic resonance spectroscopy, alters during face-name association task in patients with mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis. 53:7452016. View Article : Google Scholar : PubMed/NCBI
17	Nesteruk T, Nesteruk M, Styczynska M, Barcikowska-Kotowicz M and Walecki J: Radiological evaluation of strategic structures in patients with mild cognitive impairment and early Alzheimer's disease. Pol J Radiol. 81:288–294. 2016. View Article : Google Scholar : PubMed/NCBI
18	Minter MR, Zhang C, Leone V, Ringus DL, Zhang X, Oyler-Castrillo P, Musch MW, Liao F, Ward JF, Holtzman DM, et al: Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease. Sci Rep. 6:300282016. View Article : Google Scholar : PubMed/NCBI
19	Huang Y, Zhao Z, Wei X, Zheng Y, Yu J, Zheng J and Wang L: Long-term trihexyphenidyl exposure alters neuroimmune response and inflammation in aging rat: Relevance to age and Alzheimer's disease. J Neuroinflammation. 13:1752016. View Article : Google Scholar : PubMed/NCBI
20	Balez R, Steiner N, Engel M, Muñoz SS, Lum JS, Wu Y, Wang D, Vallotton P, Sachdev P, O'Connor M, et al: Neuroprotective effects of apigenin against inflammation, neuronal excitability and apoptosis in an induced pluripotent stem cell model of Alzheimer's disease. Sci Rep. 6:314502016. View Article : Google Scholar : PubMed/NCBI
21	Justin Thenmozhi A, William Raja TR, Manivasagam T, Janakiraman U and Essa M: Hesperidin ameliorates cognitive dysfunction, oxidative stress and apoptosis against aluminium chloride induced rat model of Alzheimer's disease. Nutr Neurosci. 20:360–368. 2017. View Article : Google Scholar : PubMed/NCBI
22	Kim SY, Yang J and Lee YC: The effects of nicergoline on corneal nerve regeneration in rat corneas after photorefractive keratectomy. Curr Eye Res. 36:29–33. 2011. View Article : Google Scholar : PubMed/NCBI
23	Nakashima T, Hattori N, Okimoto M, Yanagida J and Kohno N: Nicergoline improves dysphagia by upregulating substance P in the elderly. Medicine. 90:279–283. 2011. View Article : Google Scholar : PubMed/NCBI
24	Pilkowska E, Jakubowska T, Witkowska K and Kulczycki J: Nicergoline in the treatment of patients after a mild ischemic stroke. Neurol Neurochir Pol. 36:1075–1085. 2002.(In Polish). PubMed/NCBI
25	Felisati G, Pignataro O, Di Girolamo A, Bruno E, Alessandrini M, Guidetti G, Monzani D, Beldi AM, Mira E, Benazzo M, et al: Nicergoline in the treatment of dizziness in elderly patients. A review. Arch Gerontol Geriatr Suppl. 163–170. 2004. View Article : Google Scholar : PubMed/NCBI
26	Saletu B, Garg A and Shoeb A: Safety of nicergoline as an agent for management of cognitive function disorders. Biomed Res Int. 2014:6101032014. View Article : Google Scholar : PubMed/NCBI
27	Caraci F, Chisari M, Frasca G, Canonico PL, Battaglia A, Calafiore M, Battaglia G, Bosco P, Nicoletti F, Copani A and Sortino MA: Nicergoline, a drug used for age-dependent cognitive impairment, protects cultured neurons against beta-amyloid toxicity. Brain Res. 1047:30–37. 2005. View Article : Google Scholar : PubMed/NCBI
28	Fioravanti M and Flicker L: Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev: CD003159. 2001. View Article : Google Scholar
29	Dirani M, Nasreddine W, Abdulla F and Beydoun A: Seizure control and improvement of neurological dysfunction in Lafora disease with perampanel. Epilepsy Behav Case Rep. 2:164–166. 2014. View Article : Google Scholar : PubMed/NCBI
30	Sharma R, Ahmad G, Esteves SC and Agarwal A: Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay using bench top flow cytometer for evaluation of sperm DNA fragmentation in fertility laboratories: Protocol, reference values, and quality control. J Assist Reprod Genet. 33:291–300. 2016. View Article : Google Scholar : PubMed/NCBI
31	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
32	Wai-Hoe L, Wing-Seng L, Ismail Z and Lay-Harn G: SDS-PAGE-based quantitative assay for screening of kidney stone disease. Biol Proced Online. 11:145–160. 2009. View Article : Google Scholar : PubMed/NCBI
33	Thinnes FP: Apoptogenic interactions of plasmalemmal type-1 VDAC and Abeta peptides via GxxxG motifs induce Alzheimer's disease-a basic model of apoptosis? Wien Med Wochenschr. 161:274–276. 2011. View Article : Google Scholar : PubMed/NCBI
34	Shi LX, Wang JH and Shi XD: PI3K/AKT/mTOR pathway and pediatric T acute lymphoblastic leukemia-review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 24:1269–1274. 2016.(In Chinese). PubMed/NCBI
35	Kong J, Ren G, Jia N, Wang Y, Zhang H, Zhang W, Chen B and Cao Y: Effects of nicorandil in neuroprotective activation of PI3K/AKT pathways in a cellular model of Alzheimer's disease. Eur Neurol. 70:233–241. 2013. View Article : Google Scholar : PubMed/NCBI
36	Kitagishi Y, Nakanishi A, Ogura Y and Matsuda S: Dietary regulation of PI3K/AKT/GSK-3β pathway in Alzheimer's disease. Alzheimers Res Ther. 6:352014. View Article : Google Scholar : PubMed/NCBI
37	Li H, Kang T, Qi B, Kong L, Jiao Y, Cao Y, Zhang J and Yang J: Neuroprotective effects of ginseng protein on PI3K/Akt signaling pathway in the hippocampus of D-galactose/AlCl3 inducing rats model of Alzheimer's disease. J Ethnopharmacol. 179:162–169. 2016. View Article : Google Scholar : PubMed/NCBI
38	Zhang B, Wang Y, Li H, Xiong R, Zhao Z, Chu X, Li Q, Sun S and Chen S: Neuroprotective effects of salidroside through PI3K/Akt pathway activation in Alzheimer's disease models. Drug Des Devel Ther. 10:1335–1343. 2016.PubMed/NCBI
39	Ferencik M, Novak M, Rovensky J and Rybar I: Alzheimer's disease, inflammation and non-steroidal anti-inflammatory drugs. Bratisl Lek Listy. 102:123–132. 2001.PubMed/NCBI
40	McGeer EG and McGeer PL: Chronic inflammation in Alzheimer's disease offers therapeutic opportunities. Expert Rev Neurother. 1:53–60. 2001. View Article : Google Scholar : PubMed/NCBI
41	Quinn J, Montine T, Morrow J, Woodward WR, Kulhanek D and Eckenstein F: Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. J Neuroimmunol. 137:32–41. 2003. View Article : Google Scholar : PubMed/NCBI
42	Verdile G, Keane KN, Cruzat VF, Medic S, Sabale M, Rowles J, Wijesekara N, Martins RN, Fraser PE and Newsholme P: Inflammation and oxidative stress: The molecular connectivity between insulin resistance, obesity, and alzheimer's disease. Mediators Inflamm. 2015:1058282015. View Article : Google Scholar : PubMed/NCBI
43	Jiang L, Tang Y and Huang X: Brain cell apoptosis after cerebral hypoxia-ischemia in neonatal rat. Zhonghua YI XUE ZA ZHI. 78:567–569. 1998.(In Chinese). PubMed/NCBI
44	Zhang XQ, Zhang ZM, Yin XL, Zhang K, Cai H and Ling F: Exploring the optimal operation time for patients with hypertensive intracerebral hemorrhage: Tracking the expression and progress of cell apoptosis of prehematomal brain tissues. Chin Med J (Engl). 123:1246–1250. 2010.PubMed/NCBI
45	Johnson S, Tazik S, Lu D, Johnson C, Youdim MB, Wang J, Rajkowska G and Ou XM: The new inhibitor of monoamine oxidase, M30, has a Neuroprotective effect against dexamethasone-induced brain cell apoptosis. Front Neurosci. 4:1802010. View Article : Google Scholar : PubMed/NCBI
46	Yang S, Zhou G, Liu H, Zhang B, Li J, Cui R and Du Y: Protective effects of p38 MAPK inhibitor SB202190 against hippocampal apoptosis and spatial learning and memory deficits in a rat model of vascular dementia. Biomed Res Int. 2013:2157982013. View Article : Google Scholar : PubMed/NCBI
47	Yürüker V, Nazıroğlu M and Şenol N: Reduction in traumatic brain injury-induced oxidative stress, apoptosis, and calcium entry in rat hippocampus by melatonin: Possible involvement of TRPM2 channels. Metab Brain Dis. 30:223–231. 2015. View Article : Google Scholar : PubMed/NCBI
48	Chatterjee A, Chattopadhyay D and Chakrabarti G: MiR-16 targets Bcl-2 in paclitaxel-resistant lung cancer cells and overexpression of miR-16 along with miR-17 causes unprecedented sensitivity by simultaneously modulating autophagy and apoptosis. Cell Signal. 27:189–203. 2015. View Article : Google Scholar : PubMed/NCBI